vx-745
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02423200)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- MAP kinase p38 alphaINHIBITOR
MAPK14 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl- Mol. weight
- 436.27 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL119385 ↗
Also known as
- vx-745
- vx-745
- vx-745
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03435861 | Phase 2 | Mar 28, 2018 | Fondation Plan Alzheimer, University of Toulouse |
| NCT02423122 | Phase 2 | Apr 1, 2015 | EIP Pharma, LLC, Free University of Amsterdam |
| NCT02423200 | Phase 2 | Apr 1, 2015 | EIP Pharma, LLC, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| EIP Pharma, LLC | For profit | 2 | 2 | 1 | 2015 |
| Fondation Plan Alzheimer | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Parexel | For profit | 1 | 0 | 1 | 2015 |
| University of Toulouse | Academic/Hospital | 1 | 1 | 1 | 2018 |
5 organizations
Page 1 / 1